Report Detail
Global Metastatic Ovarian Cancer Drug Market Insights, Forecast to 2025
- RnM2910801 |
- 08 February, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
The global Metastatic Ovarian Cancer Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Metastatic Ovarian Cancer Drug market based on company, product type, end user and key regions.
This report studies the global market size of Metastatic Ovarian Cancer Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Metastatic Ovarian Cancer Drug in these regions.
This research report categorizes the global Metastatic Ovarian Cancer Drug market by top players/brands, region, type and end user. This report also studies the global Metastatic Ovarian Cancer Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Adgero Biopharmaceuticals Inc
Cellceutix Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Immune Design Corp.
Millennium Pharmaceuticals Inc
MolMed S.p.A.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
Market size by Product
E-7449
Crizotinib
CMB-305
G-305
LV-305
Others
Market size by End User
Clinic
Hospital
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Metastatic Ovarian Cancer Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Metastatic Ovarian Cancer Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Metastatic Ovarian Cancer Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Metastatic Ovarian Cancer Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Metastatic Ovarian Cancer Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Metastatic Ovarian Cancer Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Metastatic Ovarian Cancer Drug Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by Product
- 1.4.2 E-7449
- 1.4.3 Crizotinib
- 1.4.4 CMB-305
- 1.4.5 G-305
- 1.4.6 LV-305
- 1.4.7 Others
- 1.5 Market by End User
- 1.5.1 Global Metastatic Ovarian Cancer Drug Market Size Growth Rate by End User
- 1.5.2 Clinic
- 1.5.3 Hospital
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Metastatic Ovarian Cancer Drug Market Size
- 2.1.1 Global Metastatic Ovarian Cancer Drug Revenue 2014-2025
- 2.1.2 Global Metastatic Ovarian Cancer Drug Sales 2014-2025
- 2.2 Metastatic Ovarian Cancer Drug Growth Rate by Regions
- 2.2.1 Global Metastatic Ovarian Cancer Drug Sales by Regions
- 2.2.2 Global Metastatic Ovarian Cancer Drug Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Metastatic Ovarian Cancer Drug Sales by Manufacturers
- 3.1.1 Metastatic Ovarian Cancer Drug Sales by Manufacturers
- 3.1.2 Metastatic Ovarian Cancer Drug Sales Market Share by Manufacturers
- 3.1.3 Global Metastatic Ovarian Cancer Drug Market Concentration Ratio (CR5 and HHI)
- 3.2 Metastatic Ovarian Cancer Drug Revenue by Manufacturers
- 3.2.1 Metastatic Ovarian Cancer Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Metastatic Ovarian Cancer Drug Revenue Share by Manufacturers (2014-2019)
- 3.3 Metastatic Ovarian Cancer Drug Price by Manufacturers
- 3.4 Metastatic Ovarian Cancer Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Metastatic Ovarian Cancer Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Metastatic Ovarian Cancer Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Metastatic Ovarian Cancer Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Metastatic Ovarian Cancer Drug Sales by Product
- 4.2 Global Metastatic Ovarian Cancer Drug Revenue by Product
- 4.3 Metastatic Ovarian Cancer Drug Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Metastatic Ovarian Cancer Drug Breakdown Data by End User
6 North America
- 6.1 North America Metastatic Ovarian Cancer Drug by Countries
- 6.1.1 North America Metastatic Ovarian Cancer Drug Sales by Countries
- 6.1.2 North America Metastatic Ovarian Cancer Drug Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Metastatic Ovarian Cancer Drug by Product
- 6.3 North America Metastatic Ovarian Cancer Drug by End User
7 Europe
- 7.1 Europe Metastatic Ovarian Cancer Drug by Countries
- 7.1.1 Europe Metastatic Ovarian Cancer Drug Sales by Countries
- 7.1.2 Europe Metastatic Ovarian Cancer Drug Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Metastatic Ovarian Cancer Drug by Product
- 7.3 Europe Metastatic Ovarian Cancer Drug by End User
8 Asia Pacific
- 8.1 Asia Pacific Metastatic Ovarian Cancer Drug by Countries
- 8.1.1 Asia Pacific Metastatic Ovarian Cancer Drug Sales by Countries
- 8.1.2 Asia Pacific Metastatic Ovarian Cancer Drug Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Metastatic Ovarian Cancer Drug by Product
- 8.3 Asia Pacific Metastatic Ovarian Cancer Drug by End User
9 Central & South America
- 9.1 Central & South America Metastatic Ovarian Cancer Drug by Countries
- 9.1.1 Central & South America Metastatic Ovarian Cancer Drug Sales by Countries
- 9.1.2 Central & South America Metastatic Ovarian Cancer Drug Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Metastatic Ovarian Cancer Drug by Product
- 9.3 Central & South America Metastatic Ovarian Cancer Drug by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Metastatic Ovarian Cancer Drug by Countries
- 10.1.1 Middle East and Africa Metastatic Ovarian Cancer Drug Sales by Countries
- 10.1.2 Middle East and Africa Metastatic Ovarian Cancer Drug Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Metastatic Ovarian Cancer Drug by Product
- 10.3 Middle East and Africa Metastatic Ovarian Cancer Drug by End User
11 Company Profiles
- 11.1 Adgero Biopharmaceuticals Inc
- 11.1.1 Adgero Biopharmaceuticals Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
- 11.1.5 Adgero Biopharmaceuticals Inc Recent Development
- 11.2 Cellceutix Corporation
- 11.2.1 Cellceutix Corporation Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Products Offered
- 11.2.5 Cellceutix Corporation Recent Development
- 11.3 Eisai Co., Ltd.
- 11.3.1 Eisai Co., Ltd. Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Products Offered
- 11.3.5 Eisai Co., Ltd. Recent Development
- 11.4 F. Hoffmann-La Roche Ltd.
- 11.4.1 F. Hoffmann-La Roche Ltd. Company Details
- 11.4.2 Company Business Overview
- 11.4.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Products Offered
- 11.4.5 F. Hoffmann-La Roche Ltd. Recent Development
- 11.5 Immune Design Corp.
- 11.5.1 Immune Design Corp. Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Products Offered
- 11.5.5 Immune Design Corp. Recent Development
- 11.6 Millennium Pharmaceuticals Inc
- 11.6.1 Millennium Pharmaceuticals Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
- 11.6.5 Millennium Pharmaceuticals Inc Recent Development
- 11.7 MolMed S.p.A.
- 11.7.1 MolMed S.p.A. Company Details
- 11.7.2 Company Business Overview
- 11.7.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Products Offered
- 11.7.5 MolMed S.p.A. Recent Development
- 11.8 Natco Pharma Limited
- 11.8.1 Natco Pharma Limited Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Products Offered
- 11.8.5 Natco Pharma Limited Recent Development
- 11.9 Northwest Biotherapeutics, Inc.
- 11.9.1 Northwest Biotherapeutics, Inc. Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Products Offered
- 11.9.5 Northwest Biotherapeutics, Inc. Recent Development
- 11.10 Pfizer Inc.
- 11.10.1 Pfizer Inc. Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Products Offered
- 11.10.5 Pfizer Inc. Recent Development
- 11.11 Richter Gedeon Nyrt.
- 11.12 Sumitomo Dainippon Pharma Co., Ltd.
- 11.13 VG Life Sciences, Inc.
12 Future Forecast
- 12.1 Metastatic Ovarian Cancer Drug Market Forecast by Regions
- 12.1.1 Global Metastatic Ovarian Cancer Drug Sales Forecast by Regions 2019-2025
- 12.1.2 Global Metastatic Ovarian Cancer Drug Revenue Forecast by Regions 2019-2025
- 12.2 Metastatic Ovarian Cancer Drug Market Forecast by Product
- 12.2.1 Global Metastatic Ovarian Cancer Drug Sales Forecast by Product 2019-2025
- 12.2.2 Global Metastatic Ovarian Cancer Drug Revenue Forecast by Product 2019-2025
- 12.3 Metastatic Ovarian Cancer Drug Market Forecast by End User
- 12.4 North America Metastatic Ovarian Cancer Drug Forecast
- 12.5 Europe Metastatic Ovarian Cancer Drug Forecast
- 12.6 Asia Pacific Metastatic Ovarian Cancer Drug Forecast
- 12.7 Central & South America Metastatic Ovarian Cancer Drug Forecast
- 12.8 Middle East and Africa Metastatic Ovarian Cancer Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Metastatic Ovarian Cancer Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Metastatic Ovarian Cancer Drug . Industry analysis & Market Report on Metastatic Ovarian Cancer Drug is a syndicated market report, published as Global Metastatic Ovarian Cancer Drug Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Metastatic Ovarian Cancer Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
